 | |
 | |
| Clinical data | |
|---|---|
| Routes of administration | By mouth |
| Drug class | Opioid |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 21% |
| Metabolites | 7-Hydroxymitragynine |
| Eliminationhalf-life | 7–39 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C23H30N2O4 |
| Molar mass | 398.503 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 102–106 °C[3] |
| |
| |
Mitragynine is anindole-basedalkaloid and is one of the mainpsychoactive constituents in the Southeast Asian plantMitragyna speciosa, commonly known as kratom.[4] It has also been researched for its use to potentially manage symptoms ofopioid withdrawal.
Mitragynine is the most abundant active alkaloid in kratom. In Thai varieties of kratom, mitragynine is the most abundant component (up to 66% of total alkaloids), while7-hydroxymitragynine (7-OH) is a minor constituent (up to 2% of total alkaloid content). In Malaysian kratom varieties, mitragynine is present at lower concentration (12% of total alkaloids).[5] Total alkaloid concentration in dried leaves ranges from 0.5 to 1.5%. Such preparations areorally consumed and typically involve dried kratom leaves which are brewed into tea[4][5] or ground and placed intocapsules.[5]
As of April 2019[update], the USFood and Drug Administration (FDA) had stated that there were noapproved clinical uses for kratom, and that there was no evidence that kratom was safe or effective for treating any condition.[6] This reiterated the conclusion of an earlier report by theEuropean Monitoring Centre for Drugs and Drug Addiction (EMCDDA): As of 2023[update], mitragynine had not been approved for any medical use.[7][8] As of 2018[update], the FDA had noted, in particular, that there had been no clinical trials to study safety and efficacy of kratom in the treatment of opioid addiction.[9]
Mitragynine-containing kratom extracts, with their accompanying array ofalkaloids and othernatural products, have been used for theirpain-mitigation properties for at least a century.[10][11][12][4] In Southeast Asia, the consumption of mitragynine from whole leaf kratom preparations is common among laborers who report utilizing kratom's mild stimulant andanalgesic properties to increase endurance and ease pain while working.[12][4] In one laboratory study in a rat model in 2016, alkaloid-containing extracts of kratom gave evidence of inducingnaloxone-reversibleantinociceptive effects inhotplate andtail-flick tests to a level comparable tooxycodone.[13][14]
Kratom is commonly used in the United States asself-medication forpain.[15] A 2019 review of existing literature suggested the potential of kratom as substitution therapy forchronic pain.[16]
As early as the 19th century, kratom was in use for the treatment ofopioid addiction andwithdrawal.[10][4] As of 2018[update], a review of mental health aspects of kratom use mentionedopioid replacement and withdrawal as primary motivations for kratom use: almost 50% of the approximately 8,000 kratom users surveyed indicated kratom use that resulted in reduced or discontinued use ofopioids.[12][17] Some animal models of opioid withdrawal suggest mitragynine can suppress and ameliorate withdrawal from other opioid agonists (e.g., after chronic administration ofmorphine inzebra fish).[4]
Mitragynine and its metabolite7-hydroxymitragynine (7-OH) are thought to underlie the effects of kratom.[5][4] Consumption of dried kratom leaves yields different responses depending on the dose consumed.[5][4][10] At low doses, kratom is reported to induce a mild stimulating effect, while larger doses are reported to producesedation andanalgesia typical of opioids.[5][10][4] The concentration of mitragynine and other alkaloids in kratom has been found to vary between particular "strains" of the plant, thus indicating "strain-specific" effects from consumption, as well.[5] Effects of mitragynine-containing preparations fromM. speciosa includeanalgesic,anti-inflammatory,antidepressant, andmuscle relaxant properties; adverse effects include a negative impact on cognition; in animal studies the potential for misuse has been found, including through the use of theconditioned place preference (CPP) test, which indicated a distinct reward effect for 7-hydroxymitragynine.[13]
In one study, symptoms of withdrawal lasted less than three days for most subjects.[18] In an animal study, mitragynine withdrawal symptoms were observed following 14 days of mitragynineintraperitoneal injections in mice and included displays of anxiety, teeth chattering, andpiloerection, all of which are characteristic signs of opioid withdrawal in mice and are comparable tomorphine withdrawal symptoms.[18]
The solubility of mitragynine from kratom in neutral-pH and alkaline water is very low (0.0187 mg/ml at pH 9).[19] The solubility of mitragynine in acidic water is higher (3.5 mg/ml at pH 4), however, this alkaloid can become unstable, so certain products, such as low-pH beverages, have a very short shelf life.[19] Many vendors offer concentrated kratom products with claims of improved mitragynine solubility, however, those products are often formulated with solvents such as propylene glycol, which can make products unpleasant.
| Compound | Affinities (Ki (nM)Tooltip Inhibitor constant) | Ratio | Ref | ||
|---|---|---|---|---|---|
| MORTooltip μ-Opioid receptor | DORTooltip δ-Opioid receptor | KORTooltip κ-Opioid receptor | MOR:DOR:KOR | ||
| Mitragynine | 7.24 | 60.3 | 1,100 | 1:8:152 | [20] |
| 7-Hydroxymitragynine | 13.5 | 155 | 123 | 1:11:9 | [20] |
| Mitragynine pseudoindoxyl | 0.087 | 3.02 | 79.4 | 1:35:913 | [20] |
Mitragynine acts on a variety of receptors in thecentral nervous system (CNS), most notably themu,delta, andkappaopioid receptors.[21] The nature of mitragynine's interaction with opioid receptors has yet to be fully classified, with some reports suggestingpartial agonist activity at the mu-opioid receptor[10][21] and others suggesting fullagonist activity.[5] Additionally, mitragynine is known to interact withdelta andkappa opioid receptors as well, but these interactions remain ambiguous, with some reports indicating mitragynine as a delta and kappa opioid receptorcompetitive antagonist[21] and others as a full agonist of these receptors.[5] In either case, mitragynine is reported to have loweraffinity to delta and kappa opioid receptors compared to mu opioid receptors.[4] Mitragynine is also known to interact withdopamine D2,adenosine,serotonin, andalpha-2 adrenergic receptors, though the significance of these interactions is not fully understood.[21][5] Additionally, several reports of mitragynine pharmacology indicate potentialbiased agonism activity favoringG protein signaling pathways independent ofbeta arrestin recruitment,[21][11][10] which was originally thought to be a primary component in reducing opioid-inducedrespiratory depression.[21] However, recent evidence suggests that low intrinsic efficacy at the mu-opioid receptor is responsible for the improved side effect profile of mitragynine, as opposed to G protein bias.[22]
| t1⁄2 (h) | 23.24 ± 16.07 |
|---|---|
| Vd (L/kg) | 38.04 ± 24.32 |
| tmax (h) | 0.83 ± 0.35 |
| CL (L/h) | 1.4 ± 0.73 |
Pharmacokinetic analysis has largely taken place in live rodents as well as in rodent and humanmicrosomes.[21] Owing to the heterogeneity of analysis and paucity of human experiments conducted thus far, the pharmacokinetic profile of mitragynine is not complete.[21] However, initial pharmacokinetic studies in humans have yielded preliminary information.[10][21] In a study of 10 healthy volunteers taking orally administered mitragynine from whole leaf preparations, mitragynine appeared to have a much longerhalf-life than typical opioid agonists (7–39 hours) and reachedpeak plasma concentration (Tmax) within 1 hour of administration.[5] However, another study involving a Kratom tea preparation reported a much shorter half-life of 3 hours.[21] Mitragynine is estimated to have a bioavailability of 21%.[21]
.png)
| CYP | 1A2 | 3A4 | 2D6 |
|---|---|---|---|
| IC50 (μg/mL) | 39(6) | 0.78(6) | 3.6(3), 0.636(6) |
Mitragynine is primarily metabolized in the liver, producing manymetabolites during both phase I and phase II.[10]
During phase I metabolism, mitragynine undergoeshydrolysis of themethylester group on C16 as well as o-demethylation of bothmethoxy groups on positions 9 and 17.[23][4] Following this step,oxidation andreduction reactions convertaldehyde intermediates into alcohols andcarboxylic acids.[4]P450 metabolic enzymes are known to facilitate thephase I metabolism of mitragynine which reportedly has an inhibitory effect on multiple P450 enzymes, raising the possibility of adverse drug interactions.[24][4][21]
Duringphase II metabolism, phase I metabolites undergoglucuronidation andsulfation to form multiple glucuronide and sulfate conjugates, which are then excreted via urine.[21][4]
Mitragynine consumption for medicinal and recreational purposes dates back centuries, although early use was primarily limited to Southeast Asian countries such asIndonesia andThailand, where the plant grows indigenously.[10] Recently, mitragynine use has spread throughout Europe and the Americas as both a recreational and medicinal drug.[11] While research into the effects of kratom have begun to emerge, investigations on the active compound mitragynine are less common.
 | The examples and perspective in this sectiondeal primarily with US-centric section and do not represent aworldwide view of the subject. You mayimprove this section, discuss the issue on thetalk page, or create a new section, as appropriate.(July 2025) (Learn how and when to remove this message) |
In theUnited States,kratom and its active ingredients are not scheduled underDEA guidelines. Despite the current legal status of the plant and its constituents, the legality of kratom has been turbulent in recent years. In August 2016, the DEA issued a report of intent stating that mitragynine and7-hydroxymitragynine would undergo emergency scheduling and be placed underSchedule I classification until further notice, making kratom strictly illegal and thus hindering research on its active constituents.[25][11] Following this report, the DEA faced significant public and administrative opposition in the form of aWhite House petition signed by 140,000 citizens and a letter to the DEA administrator backed by 51 members of theHouse of Representatives resisting the proposed scheduling.[25][26][27] This opposition led the DEA to withdraw its report of intent in October 2016, allowing for unencumbered research into the potential benefits and health risks associated with mitragynine and other alkaloids in the kratom plant.[25][11][28] Kratom and its active constituents are unscheduled and legally sold in stores and online in the United States except for a small number of states.[29] As of June 2019, theFDA continues to warn consumers not to use kratom, while advocating for more research for a better understanding of kratom's safety profile.[30]
Inconsistencies in dosing, purity, and concomitant drug use makes evaluating the effects of mitragynine in humans difficult. Conversely, animal studies control for such variability, but offer limited translatable information relevant to humans.[21] Experimental limitations aside, mitragynine has been found to interact with a variety of receptors, although the nature and extent of receptor interactions has yet to be fully characterized.[5] Additionally, the toxicity of mitragynine and associated kratom alkaloids has yet to be fully determined in humans, nor has the risk ofoverdose.[31] More studies are necessary to assess safety and potential therapeutic utility.[32]
Mitragynine toxicity in humans is largely unknown, as animal studies show significant species-specific differences in mitragynine tolerance.[5] Mitragynine toxicity in humans is rarely reported although specific examples of seizures andliver toxicity in kratom consumers have been reported.[33][31] Due tocytochrome P450 enzyme inhibition, the combination of mitragynine with other drugs poses concern for adverse reactions to mitragynine.[24][4][5][21] Fatalities involving mitragynine tend to include its use in combination with opioids and somecough suppressants.[5] Post-mortemtoxicology screens indicate a wide range of mitragynine blood concentrations ranging from 10 μg/L to 4800 μg/L, making it difficult to calculate what constitutes a toxic dose in humans.[31] These variations are suggested to result from differences in the toxicology assays used, and how long after death the assays were conducted.[31]
